MedTrace Logo

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

NCT00989690 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 275

Last updated 2013-08-12

No results posted yet for this study

Summary

RATIONALE: Studying the proteins expressed in samples of blood and tissue from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This randomized phase III trial is studying blood and tissue samples in predicting response to second-line therapy using erlotinib hydrochloride or chemotherapy in patients with advanced non-small cell lung cancer.

Conditions

Interventions

DRUG

docetaxel

DRUG

erlotinib hydrochloride

DRUG

pemetrexed disodium

GENETIC

fluorescence in situ hybridization

GENETIC

mutation analysis

GENETIC

proteomic profiling

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

OTHER

matrix-assisted laser desorption/ionization time of flight mass spectrometry

PROCEDURE

breath test

Sponsors & Collaborators

  • Istituto Scientifico H. San Raffaele

    lead OTHER

Principal Investigators

  • Vanesa Gregor, MD · Istituto Scientifico H. San Raffaele

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00989690 on ClinicalTrials.gov